Clinical trial
Pravastatin for Hyperlipidaemia in HIV.
NCT00227500 · Kirby Institute, Other · Completed
Key facts
| NCT number | NCT00227500 |
|---|---|
| Title | Pravastatin for Hyperlipidaemia in HIV. |
| Official title | A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV |
| Lead sponsor | Kirby Institute, Other |
| Collaborators | The University of New South Wales National Heart, Lung, and Blood Institute (NHLBI) NIH Garvan Institute of Medical Research St Vincent's Hospital, Sydney |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections, Lipid Metabolism, Glucose Metabolism, Metabolic Abnormality, Lipodystrophy, Cardiovascular Disease |
| Intervention type | Drug |
| Interventions | Pravastatin |
| Enrollment | 40 |
| Start date | Jul 1, 2001 |
| Completion | Oct 1, 2004 |
| First posted | Sep 28, 2005 |
| Last update posted | Jun 9, 2006 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: